Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – Still a Buy?

Posted by Francis Steltz on Sep 23rd, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $13.50, but opened at $13.94. Oric Pharmaceuticals shares last traded at $13.3950, with a volume of 89,718 shares.

Wall Street Analyst Weigh In

ORIC has been the subject of several recent analyst reports. Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a report on Friday, June 12th. They issued a “buy” rating and a $14.00 price target for the company. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. HC Wainwright lifted their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.18.

Check Out Our Latest Stock Analysis on ORIC

Oric Pharmaceuticals Stock Performance

The stock’s fifty day simple moving average is $12.64 and its two-hundred day simple moving average is $10.84. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -9.76 and a beta of 1.00.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). Analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.70% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Quantinno Capital Management LP increased its stake in Oric Pharmaceuticals by 9.3% during the first quarter. Quantinno Capital Management LP now owns 25,526 shares of the company’s stock valued at $323,000 after purchasing an additional 2,170 shares during the last quarter. Bank of New York Mellon Corp increased its position in Oric Pharmaceuticals by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 190,470 shares of the company’s stock valued at $2,413,000 after acquiring an additional 2,549 shares during the period. ProShare Advisors LLC raised its stake in shares of Oric Pharmaceuticals by 22.5% during the fourth quarter. ProShare Advisors LLC now owns 16,392 shares of the company’s stock valued at $134,000 after purchasing an additional 3,009 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Oric Pharmaceuticals during the 2nd quarter worth about $38,000. Finally, Quantbot Technologies LP acquired a new stake in Oric Pharmaceuticals in the second quarter worth approximately $46,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.

Oric’s research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).